Assessing the order of critical alterations in prostate cancer development and progression by IHC: Further evidence that PTEN loss occurs subsequent to ERG gene fusion

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 2, 2013, Pages 209-215

  Gumuskaya, B ^a   Gurel, B ^a   Fedor, H ^a   Tan, H L ^b   Weier, C A ^a   Hicks, J L ^b   Haffner, M C ^a   Lotan, T L ^a   De Marzo, A M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

cancer clonality; ERG; FISH; immunohistochemistry; PTEN

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR ERG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; ERG GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE FREQUENCY; GENE FUSION; GENE LOCUS; GENE LOSS; GENE REARRANGEMENT; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PHOSPHATASE AND TENSIN HOMOLOG DELETED ON CHROMOSOME 10 GENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN DEPLETION; PROTEIN FUNCTION;

ADENOCARCINOMA; ADULT; AGED; CARCINOGENESIS; DISEASE PROGRESSION; GENE DELETION; HOMOZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ONCOGENE FUSION; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; TRANS-ACTIVATORS;

EID: 84882450258     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.8     Document Type: Article

References (37)

1. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481: 306-313.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
3. Jan M, Majeti R. Clonal evolution of acute leukemia genomes. Oncogene 2012; 32: 135-140.
4. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648. (Pubitemid 41528150)
5. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-390.
6. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954-2963. (Pubitemid 41079915)
7. Yoshimoto M, Ludkovski O, DeGrace D, Williams JL, Evans A, Sircar K et al. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes Cancer 2012; 51: 149-160.
8. Reid AH, Attard G, Brewer D, Miranda S, Riisnaes R, Clark J et al. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Mod Pathol 2012; 25: 902-910.
9. Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 2010; 13: 228-237.
10. Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 2007; 67: 7991-7995. (Pubitemid 47395131)
11. Barry M, Perner S, Demichelis F, Rubin MA. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 2007; 70: 630-633. (Pubitemid 350030260)
12. Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008; 21: 67-75. (Pubitemid 351172158)
13. Bismar TA, Yoshimoto M, Vollmer RT, Duan Q, Firszt M, Corcos J et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int 2011; 107: 477-485.
14. Carver BS, Tran J, Chen Z, Carracedo-Perez A, Alimonti A, Nardella C et al. ETS rearrangements and prostate cancer initiation. Nature 2009; 457: E1.
15. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS et al. Tomlins et al. reply. Nature 2009; 457: 2.
16. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R et al. Antibodybased detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010; 12: 590-598.
17. van Leenders GJ, Boormans JL, Vissers CJ, Hoogland AM, Bressers AA, Furusato B et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol 2011; 24: 1128-1138.
18. Falzarano SM, Zhou M, Hernandez AV, Klein EA, Rubin MA, Magi-Galluzzi C. Single focus prostate cancer: pathological features and ERG fusion status. J Urol 2011; 185: 489-494.
19. Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol 2011; 35: 1014-1020.
20. Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 2011; 17: 6563-6573.
21. Sangale Z, Prass C, Carlson A, Tikishvili E, Degrado J, Lanchbury J et al. A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl Immunohistochem Mol Morphol 2011; 19: 173-183.
22. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011; 24: 820-828.
23. Qu X, Randhawa G, Friedman C, OHara-Larrivee S, Kroeger K, Dumpit R et al. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer. Cancer Genet 2013; 206: 1-11.
24. Yoshimoto M, Ding K, Sweet JM, Ludkovski O, Trottier G, Song KS et al. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol 2012; 26: 435-447.
25. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138-141. (Pubitemid 23098782)
26. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510.
27. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011; 20: 810-817.
28. Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009; 22: 1083-1093.
29. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007; 97: 678-685. (Pubitemid 47339893)
30. Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010; 102: 678-684.
31. Albadine R, Latour M, Toubaji A, Haffner M, Isaacs WB, AP E et al. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Mod Pathol 2009; 22: 1415-1422.
32. Toubaji A, Albadine R, Meeker AK, Isaacs WB, Lotan T, Haffner MC et al. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod Pathol 2011; 24: 1511-1520.
33. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009; 15: 559-565.
34. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998; 58: 204-209. (Pubitemid 28047054)
35. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J et al. TMPRSS2- ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007; 31: 882-888. (Pubitemid 47165141)
36. Yoshimoto M, Cutz JC, Nuin PA, Joshua AM, Bayani J, Evans AJ et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 2006; 169: 128-137. (Pubitemid 44287105)
37. Lotan TL, Gumuskaya B, Rahimi H, Hicks JL, Iwata T, Robinson BD et al. Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Mod Pathol 2012. (e-pub ahead of print).